LIPOSARCOMA, DEDIFFERENTIATED
Clinical trials for LIPOSARCOMA, DEDIFFERENTIATED explained in plain language.
Never miss a new study
Get alerted when new LIPOSARCOMA, DEDIFFERENTIATED trials appear
Sign up with your email to follow new studies for LIPOSARCOMA, DEDIFFERENTIATED, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New pill shows promise in rare cancer fight
Disease control CompletedThis study tested a new cancer pill, brigimadlin, against standard chemo (doxorubicin) in 400 adults with advanced dedifferentiated liposarcoma. Participants took either the pill or received chemo infusions every 3 weeks. The goal was to see which treatment better slowed tumor gr…
Matched conditions: LIPOSARCOMA, DEDIFFERENTIATED
Phase: PHASE2, PHASE3 • Sponsor: Boehringer Ingelheim • Aim: Disease control
Last updated Jun 27, 2026 09:09 UTC
-
New combo therapy shows promise for rare liposarcoma
Disease control CompletedThis phase 2 study tested whether adding pioglitazone (a diabetes drug) to trabectedin (a chemotherapy) could help shrink or control liposarcoma, a rare cancer of fat tissue. The study included 10 patients whose tumors had stopped growing but not shrunk with trabectedin alone. Re…
Matched conditions: LIPOSARCOMA, DEDIFFERENTIATED
Phase: PHASE2 • Sponsor: Mario Negri Institute for Pharmacological Research • Aim: Disease control
Last updated Jun 27, 2026 09:06 UTC
-
Promising new pill targets rare cancer in phase 3 trial
Disease control CompletedThis study tested a new cancer pill called brigimadlin in 138 adults with a rare type of fat-tissue cancer (dedifferentiated liposarcoma). The pill works by blocking a protein that helps the cancer grow. Participants took the pill once every three weeks, and doctors monitored sid…
Matched conditions: LIPOSARCOMA, DEDIFFERENTIATED
Phase: PHASE3 • Sponsor: Boehringer Ingelheim • Aim: Disease control
Last updated Jun 27, 2026 08:10 UTC